Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Simoes C, Paiva B, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Villar S, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Montesinos P.
Simoes C, et al. Among authors: tormo m.
Blood Adv. 2021 Feb 9;5(3):760-770. doi: 10.1182/bloodadvances.2020003195.
Blood Adv. 2021.
PMID: 33560390
Free PMC article.
Clinical Trial.